Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD

Stuart G. Beattie, Eric Goetzman, Thomas Conlon, Sean Germain, Glenn Walter, Martha Campbell-Thompson, Dietrich Matern, Jerry Vockley, Terence R. Flotte

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recombinant adeno-associated viral vectors pseudotyped with serotype 5 and 8 capsids (AAV5 and AAV8) have been shown to be efficient gene transfer reagents for the liver. We have produced AAV5 and AAV8 vectors that express mouse short-chain acyl-CoA dehydrogenase (mSCAD) cDNA under the transcriptional control of the cytomegalovirus-chicken β-actin hybrid promoter. We hypothesized that these vectors would produce sufficient hepatocyte transduction (after administration via the portal vein) and thus sufficient SCAD enzyme to correct the phenotype observed in the SCAD-deficient (BALB/cByJ) mouse, which includes elevated blood butyrylcarnitine and hepatic steatosis. Ten weeks after portal vein injection into 8-week-old mice, AAV8-treated livers contained acyl-CoA dehydrogenase activity (14.3 mU/mg) toward butyryl-CoA, compared with 7.6 mU/mg in mice that received phosphate-buffered saline. Immunohistochemistry showed expression of mSCAD within rAAV8-mSCAD-transduced hepatocytes, as seen by light microscopy. A significant reduction of circulating butyrylcarnitine was seen in AAV5-mSCAD- and AAV8-mSCAD-injected mice. Magnetic resonance spectroscopy of fasted mice demonstrated a significant reduction in relative lipid content within the livers of AAV8-mSCAD-treated mice. These results demonstrate biochemical correction of SCAD deficiency after AAV8-mediated SCAD gene delivery.

Original languageEnglish (US)
Pages (from-to)579-588
Number of pages10
JournalHuman Gene Therapy
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Portal Vein
Butyryl-CoA Dehydrogenase
Injections
Liver
Short chain Acyl CoA dehydrogenase deficiency
Hepatocytes
Acyl-CoA Dehydrogenase
Capsid
Cytomegalovirus
Genes
Actins
Microscopy
Chickens
Magnetic Resonance Spectroscopy
Complementary DNA
Immunohistochemistry
Phosphates
Phenotype
Lipids
Light

ASJC Scopus subject areas

  • Genetics

Cite this

Beattie, S. G., Goetzman, E., Conlon, T., Germain, S., Walter, G., Campbell-Thompson, M., ... Flotte, T. R. (2008). Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD. Human Gene Therapy, 19(6), 579-588. https://doi.org/10.1089/hum.2007.168

Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD. / Beattie, Stuart G.; Goetzman, Eric; Conlon, Thomas; Germain, Sean; Walter, Glenn; Campbell-Thompson, Martha; Matern, Dietrich; Vockley, Jerry; Flotte, Terence R.

In: Human Gene Therapy, Vol. 19, No. 6, 01.06.2008, p. 579-588.

Research output: Contribution to journalArticle

Beattie, SG, Goetzman, E, Conlon, T, Germain, S, Walter, G, Campbell-Thompson, M, Matern, D, Vockley, J & Flotte, TR 2008, 'Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD', Human Gene Therapy, vol. 19, no. 6, pp. 579-588. https://doi.org/10.1089/hum.2007.168
Beattie, Stuart G. ; Goetzman, Eric ; Conlon, Thomas ; Germain, Sean ; Walter, Glenn ; Campbell-Thompson, Martha ; Matern, Dietrich ; Vockley, Jerry ; Flotte, Terence R. / Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD. In: Human Gene Therapy. 2008 ; Vol. 19, No. 6. pp. 579-588.
@article{3abda0586d8f4df1957b7a5aad4f92ec,
title = "Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD",
abstract = "Recombinant adeno-associated viral vectors pseudotyped with serotype 5 and 8 capsids (AAV5 and AAV8) have been shown to be efficient gene transfer reagents for the liver. We have produced AAV5 and AAV8 vectors that express mouse short-chain acyl-CoA dehydrogenase (mSCAD) cDNA under the transcriptional control of the cytomegalovirus-chicken β-actin hybrid promoter. We hypothesized that these vectors would produce sufficient hepatocyte transduction (after administration via the portal vein) and thus sufficient SCAD enzyme to correct the phenotype observed in the SCAD-deficient (BALB/cByJ) mouse, which includes elevated blood butyrylcarnitine and hepatic steatosis. Ten weeks after portal vein injection into 8-week-old mice, AAV8-treated livers contained acyl-CoA dehydrogenase activity (14.3 mU/mg) toward butyryl-CoA, compared with 7.6 mU/mg in mice that received phosphate-buffered saline. Immunohistochemistry showed expression of mSCAD within rAAV8-mSCAD-transduced hepatocytes, as seen by light microscopy. A significant reduction of circulating butyrylcarnitine was seen in AAV5-mSCAD- and AAV8-mSCAD-injected mice. Magnetic resonance spectroscopy of fasted mice demonstrated a significant reduction in relative lipid content within the livers of AAV8-mSCAD-treated mice. These results demonstrate biochemical correction of SCAD deficiency after AAV8-mediated SCAD gene delivery.",
author = "Beattie, {Stuart G.} and Eric Goetzman and Thomas Conlon and Sean Germain and Glenn Walter and Martha Campbell-Thompson and Dietrich Matern and Jerry Vockley and Flotte, {Terence R.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1089/hum.2007.168",
language = "English (US)",
volume = "19",
pages = "579--588",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD

AU - Beattie, Stuart G.

AU - Goetzman, Eric

AU - Conlon, Thomas

AU - Germain, Sean

AU - Walter, Glenn

AU - Campbell-Thompson, Martha

AU - Matern, Dietrich

AU - Vockley, Jerry

AU - Flotte, Terence R.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Recombinant adeno-associated viral vectors pseudotyped with serotype 5 and 8 capsids (AAV5 and AAV8) have been shown to be efficient gene transfer reagents for the liver. We have produced AAV5 and AAV8 vectors that express mouse short-chain acyl-CoA dehydrogenase (mSCAD) cDNA under the transcriptional control of the cytomegalovirus-chicken β-actin hybrid promoter. We hypothesized that these vectors would produce sufficient hepatocyte transduction (after administration via the portal vein) and thus sufficient SCAD enzyme to correct the phenotype observed in the SCAD-deficient (BALB/cByJ) mouse, which includes elevated blood butyrylcarnitine and hepatic steatosis. Ten weeks after portal vein injection into 8-week-old mice, AAV8-treated livers contained acyl-CoA dehydrogenase activity (14.3 mU/mg) toward butyryl-CoA, compared with 7.6 mU/mg in mice that received phosphate-buffered saline. Immunohistochemistry showed expression of mSCAD within rAAV8-mSCAD-transduced hepatocytes, as seen by light microscopy. A significant reduction of circulating butyrylcarnitine was seen in AAV5-mSCAD- and AAV8-mSCAD-injected mice. Magnetic resonance spectroscopy of fasted mice demonstrated a significant reduction in relative lipid content within the livers of AAV8-mSCAD-treated mice. These results demonstrate biochemical correction of SCAD deficiency after AAV8-mediated SCAD gene delivery.

AB - Recombinant adeno-associated viral vectors pseudotyped with serotype 5 and 8 capsids (AAV5 and AAV8) have been shown to be efficient gene transfer reagents for the liver. We have produced AAV5 and AAV8 vectors that express mouse short-chain acyl-CoA dehydrogenase (mSCAD) cDNA under the transcriptional control of the cytomegalovirus-chicken β-actin hybrid promoter. We hypothesized that these vectors would produce sufficient hepatocyte transduction (after administration via the portal vein) and thus sufficient SCAD enzyme to correct the phenotype observed in the SCAD-deficient (BALB/cByJ) mouse, which includes elevated blood butyrylcarnitine and hepatic steatosis. Ten weeks after portal vein injection into 8-week-old mice, AAV8-treated livers contained acyl-CoA dehydrogenase activity (14.3 mU/mg) toward butyryl-CoA, compared with 7.6 mU/mg in mice that received phosphate-buffered saline. Immunohistochemistry showed expression of mSCAD within rAAV8-mSCAD-transduced hepatocytes, as seen by light microscopy. A significant reduction of circulating butyrylcarnitine was seen in AAV5-mSCAD- and AAV8-mSCAD-injected mice. Magnetic resonance spectroscopy of fasted mice demonstrated a significant reduction in relative lipid content within the livers of AAV8-mSCAD-treated mice. These results demonstrate biochemical correction of SCAD deficiency after AAV8-mediated SCAD gene delivery.

UR - http://www.scopus.com/inward/record.url?scp=46249123631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249123631&partnerID=8YFLogxK

U2 - 10.1089/hum.2007.168

DO - 10.1089/hum.2007.168

M3 - Article

C2 - 18500942

AN - SCOPUS:46249123631

VL - 19

SP - 579

EP - 588

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 6

ER -